Cognito Therapeutics has raised $50 million in funding as it seeks to advance treatments for an elusive target: cognitive decline.
Cognito, based in Cambridge, Mass., is developing a headset that feeds a patient light and sound to drive changes in the brains of people with Alzheimer’s disease and other neurological conditions. Cognito will use the new funding from Menlo Park-based FoundersX to complete clinical trials it can submit to the Food and Drug Administration for approval. And with its new Silicon Valley connections comes a techy confidence that the company is sitting on a potential gold mine of data that could lead to a better understanding of the brain and how to treat the diseases that damage it.
“As we start to understand how patients interact with our exogenous stimulation, we’re going to build the world’s largest data set for understanding what’s necessary to personalize dose across and within patients over time,” said CEO Brent Vaughan. “And so there is the ability to build very large data network effects.”
About the Author Reprints
Create a display name to comment
This name will appear with your comment
